Pfizer Inc.’s “extraordinary cooperation” in disclosing and dealing with a subsidiary’s improper payments to foreign officials helped the company obtain a deferred prosecution agreement for violations of the U.S. Foreign Corrupt Practices Act.
On Aug. 7, Pfizer settled two parallel investigations by the U.S. Department of Justice and the Securities and Exchange Commission...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?